Clinical Trial Update: Extract of Ginkgo Biloba and Tardive Dyskinesia [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating a Ginkgo biloba extract for tardive dyskinesia (in patients with schizophrenia) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia
• Tardive Dyskinesia

Drugs mentioned

• Ginkgo biloba extract (Ginkgo biloba extract)

Snippet

Sponsor: Beijing HuiLongGuan Hospital | Conditions: Tardive Dyskinesia, Schizophrenia | Phase 3 | Status: COMPLETED